Nutriband (NTRB) Projected to Post Quarterly Earnings on Tuesday

Nutriband (NASDAQ:NTRB) is anticipated to post its results before the market opens on Tuesday, December 2nd. Analysts expect Nutriband to post earnings of ($2.13) per share for the quarter.

Nutriband (NASDAQ:NTRB) last issued its quarterly earnings results on Tuesday, September 9th. The company reported ($2.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.95). Nutriband had a negative net margin of 398.29% and a negative return on equity of 85.40%. The business had revenue of $0.62 million during the quarter, compared to analyst estimates of $0.71 million. On average, analysts expect Nutriband to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nutriband Stock Up 1.9%

NTRB stock opened at $4.94 on Monday. The firm has a market cap of $59.48 million, a PE ratio of -1.72 and a beta of 1.89. Nutriband has a 12 month low of $3.72 and a 12 month high of $11.78. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.78 and a quick ratio of 4.70. The firm has a 50 day simple moving average of $6.57 and a 200 day simple moving average of $6.98.

Institutional Investors Weigh In On Nutriband

A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. grew its position in shares of Nutriband Inc. (NASDAQ:NTRB) by 1.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 202,738 shares of the company’s stock after buying an additional 3,111 shares during the quarter. Vanguard Group Inc. owned approximately 1.68% of Nutriband worth $1,429,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 19.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NTRB. Weiss Ratings restated a “sell (d-)” rating on shares of Nutriband in a report on Wednesday, October 8th. Zacks Research upgraded shares of Nutriband from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, Wall Street Zen lowered Nutriband from a “hold” rating to a “sell” rating in a report on Friday, September 26th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $13.00.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.